Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 03, 2023 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Receives Two Grants to Further Explore the Role of Epigenetic Targets in the Treatment of Neuronal Pathologies

Two collaborative projects with public research centers with a global budget of 2.3 million eurosOryzon to receive up to 1.4 million eurosFocused on the discovery and validation of novel biomarkers...
October 02, 2023 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Provide Corporate Progress Updates at Several Events in October

East-West Biopharma Summit 36th European College of Neuropsychopharmacology congress (ECNP 2023)Investor Access 2023 EventJefferies Inaugural Biotech CNS/Neuro Summit Roth Capital Partners 2nd...
September 05, 2023 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Give Updates on Corporate Progress in September

H.C. Wainwright Global Investment Conference in NYCSachs Annual Biotech in Europe Forum in BaselThird Annual Global CMT Research Convention in BostonBioSpain-2023 in Barcelona MADRID, Spain and...
July 26, 2023 08:00 ET | Source: Oryzon Genomics, S.A.

Oryzon Announces Completed Patient Recruitment in the PORTICO Phase IIb Trial of vafidemstat in Borderline Personality Disorder

Full recruitment secures the target number of completer patientsMultiple primary endpoints include reduction in agitation and aggression and overall disease improvementTopline efficacy data expected...
July 24, 2023 12:47 ET | Source: Oryzon Genomics, S.A.

ORYZON Reports Financial Results and Corporate Updates for Half-Year Ending June 30, 2023

Positive aggregate safety data from vafidemstat's PORTICO Phase IIb trial in Borderline Personality Disorder (BPD), consistent with safety data from seven completed clinical trials, supporting the...
July 05, 2023 08:00 ET | Source: Oryzon Genomics, S.A.

Positive Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder

Recommendation from the independent Data Monitoring Committee (DMC) to continue the PORTICO trial based on positive safety data from the initial 167 randomized patientsPORTICO plans to recruit 188...
June 27, 2023 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON Announces Voting Results from its 2023 Annual General Meeting of Shareholders

All resolutions were approved.35% of the issued shares represented. MADRID, Spain and BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a...
June 21, 2023 08:00 ET | Source: Oryzon Genomics, S.A.

Positive Preclinical Data of ORY-4001 for the Treatment of Charcot-Marie-Tooth (CMT) Disease Presented at the 2023 Peripheral Nerve Society (PNS) Annual Meeting

Comprehensively reversed disease progression symptoms in a CMT mice modelSelected for an oral presentationA highly selective and safe HDAC-6 inhibitorTo start IND-enabling studies soon MADRID,...
May 30, 2023 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Present Positive Preclinical Efficacy Data of ORY-4001 in Charcot-Marie-Tooth (CMT) Disease at the 2023 Peripheral Nerve Society (PNS) Annual Meeting

Selected for Oral PresentationStudy done in the CMT1A mouse modelSupported by the CMT Research Foundation MADRID, Spain and BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN...
May 17, 2023 08:00 ET | Source: Oryzon Genomics, S.A.

ORYZON to Present Trial in Progress Phase Ib FRIDA Study at the Upcoming 2023 ASCO Annual Meeting

MADRID, Spain and BOSTON, May 17, 2023 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop...